SUNHERE(SZ:300452)2025-04-29 09:30Financial Performance - The company reported a decline in performance for 2024, primarily due to goodwill impairment and convertible bond interest expenses, which significantly impacted operating results [2][21]. - Excluding these factors, the company maintained stable profit growth, despite a challenging market environment [21]. - The pharmaceutical industry faced a consumption slowdown, with a reported revenue growth rate of 3.0% and a profit decline of 8.3% for the drug auxiliary materials and packaging industry in 2024 [10]. Market Position and Strategy - The company holds a leading position in the solid preparation drug auxiliary materials sector, with 47 products and 27 products passing related reviews [10]. - The company has successfully helped clients achieve over 170 projects for domestic substitution of imported auxiliary materials, enhancing supply chain stability and reducing costs [29]. - The domestic market for drug auxiliary materials still relies heavily on imports, indicating significant potential for growth in domestic production [29]. Product Development and Innovation - The company is focusing on high-end drug auxiliary materials and new product development, particularly in areas like injectable materials and transdermal patches [18]. - There is an emphasis on expanding applications of existing products in new sectors such as medical beauty, daily chemicals, and animal protection [18]. - The company is actively exploring opportunities for capital cooperation to enhance its market position and profitability [20]. Investor Relations and Market Confidence - The company has implemented measures for market value management, including share buybacks and increased cash dividends, with a proposed cash dividend of 3.0 RMB per 10 shares for 2024, totaling approximately 69.79 million RMB [22]. - The company is committed to maintaining effective communication with investors and addressing concerns regarding stock price fluctuations influenced by macroeconomic factors [13][21]. - The management remains optimistic about future growth opportunities, particularly in response to increasing demand for domestic substitutes and new product lines [20][29].